Stem definition | Drug id | CAS RN |
---|---|---|
spasmolytics with a papaverine-like action | 2028 | 5633-20-5 |
Dose | Unit | Route |
---|---|---|
15 | mg | O |
3.90 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.93 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 6 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.85 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 7.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 16, 1975 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 258.69 | 10.89 | 563 | 40323 | 223457 | 50340781 |
Multiple sclerosis relapse | 236.32 | 10.89 | 228 | 40658 | 42736 | 50521502 |
Fall | 213.69 | 10.89 | 674 | 40212 | 334258 | 50229980 |
Multiple sclerosis | 165.02 | 10.89 | 135 | 40751 | 20358 | 50543880 |
Urinary incontinence | 117.55 | 10.89 | 129 | 40757 | 28079 | 50536159 |
Dry mouth | 105.41 | 10.89 | 174 | 40712 | 56004 | 50508234 |
Application site erythema | 97.65 | 10.89 | 55 | 40831 | 4483 | 50559755 |
Systemic lupus erythematosus | 87.25 | 10.89 | 7 | 40879 | 140615 | 50423623 |
Maternal exposure during pregnancy | 81.96 | 10.89 | 15 | 40871 | 159763 | 50404475 |
Gait disturbance | 71.81 | 10.89 | 275 | 40611 | 149730 | 50414508 |
Joint swelling | 70.39 | 10.89 | 57 | 40829 | 245229 | 50319009 |
Synovitis | 67.14 | 10.89 | 10 | 40876 | 123855 | 50440383 |
Balance disorder | 64.29 | 10.89 | 162 | 40724 | 70428 | 50493810 |
Glossodynia | 63.41 | 10.89 | 9 | 40877 | 115560 | 50448678 |
Urine analysis abnormal | 60.81 | 10.89 | 40 | 40846 | 4310 | 50559928 |
Exposure during pregnancy | 56.65 | 10.89 | 14 | 40872 | 121001 | 50443237 |
Micturition urgency | 51.42 | 10.89 | 47 | 40839 | 8217 | 50556021 |
Application site pruritus | 48.77 | 10.89 | 33 | 40853 | 3726 | 50560512 |
Abdominal discomfort | 48.48 | 10.89 | 70 | 40816 | 231571 | 50332667 |
Drug intolerance | 48.07 | 10.89 | 64 | 40822 | 219040 | 50345198 |
Neurogenic bladder | 46.71 | 10.89 | 29 | 40857 | 2828 | 50561410 |
Laboratory test abnormal | 46.38 | 10.89 | 74 | 40812 | 23134 | 50541104 |
Secondary progressive multiple sclerosis | 43.49 | 10.89 | 21 | 40865 | 1245 | 50562993 |
Treatment failure | 43.31 | 10.89 | 29 | 40857 | 137608 | 50426630 |
Bladder disorder | 43.26 | 10.89 | 41 | 40845 | 7502 | 50556736 |
Infusion related reaction | 43.13 | 10.89 | 44 | 40842 | 169513 | 50394725 |
Hepatic enzyme increased | 41.83 | 10.89 | 30 | 40856 | 137350 | 50426888 |
Pollakiuria | 40.90 | 10.89 | 71 | 40815 | 23780 | 50540458 |
Mental status changes | 40.33 | 10.89 | 90 | 40796 | 36182 | 50528056 |
Product adhesion issue | 39.75 | 10.89 | 31 | 40855 | 4361 | 50559877 |
Off label use | 39.29 | 10.89 | 224 | 40662 | 474202 | 50090036 |
Hypertonic bladder | 38.12 | 10.89 | 26 | 40860 | 2974 | 50561264 |
Pericarditis | 37.02 | 10.89 | 9 | 40877 | 78680 | 50485558 |
Muscular weakness | 36.60 | 10.89 | 163 | 40723 | 94850 | 50469388 |
Depression | 35.47 | 10.89 | 242 | 40644 | 165181 | 50399057 |
White blood cells urine positive | 34.43 | 10.89 | 29 | 40857 | 4549 | 50559689 |
Wound | 32.33 | 10.89 | 23 | 40863 | 105771 | 50458467 |
Urine leukocyte esterase positive | 32.00 | 10.89 | 23 | 40863 | 2860 | 50561378 |
Hallucination | 31.48 | 10.89 | 96 | 40790 | 46561 | 50517677 |
Escherichia urinary tract infection | 30.84 | 10.89 | 40 | 40846 | 10355 | 50553883 |
Culture urine positive | 30.46 | 10.89 | 24 | 40862 | 3427 | 50560811 |
Bladder spasm | 29.87 | 10.89 | 17 | 40869 | 1413 | 50562825 |
Malignant neoplasm progression | 29.77 | 10.89 | 9 | 40877 | 68115 | 50496123 |
Incontinence | 28.97 | 10.89 | 38 | 40848 | 9947 | 50554291 |
Application site rash | 28.94 | 10.89 | 20 | 40866 | 2337 | 50561901 |
Asthenia | 28.65 | 10.89 | 388 | 40498 | 318654 | 50245584 |
Cerebral atrophy | 28.30 | 10.89 | 26 | 40860 | 4575 | 50559663 |
Dysuria | 27.60 | 10.89 | 67 | 40819 | 28437 | 50535801 |
Urinary retention | 26.92 | 10.89 | 63 | 40823 | 26127 | 50538111 |
Muscle spasticity | 26.69 | 10.89 | 49 | 40837 | 17135 | 50547103 |
Gait inability | 26.69 | 10.89 | 78 | 40808 | 36949 | 50527289 |
Arthralgia | 26.49 | 10.89 | 227 | 40659 | 438475 | 50125763 |
Rheumatoid arthritis | 26.48 | 10.89 | 80 | 40806 | 202470 | 50361768 |
Band neutrophil percentage increased | 26.46 | 10.89 | 9 | 40877 | 212 | 50564026 |
Arthropathy | 26.37 | 10.89 | 55 | 40831 | 157851 | 50406387 |
Duodenal ulcer perforation | 26.34 | 10.89 | 3 | 40883 | 45608 | 50518630 |
Monocyte percentage increased | 26.21 | 10.89 | 14 | 40872 | 1027 | 50563211 |
Confusional state | 26.17 | 10.89 | 247 | 40639 | 185681 | 50378557 |
Cystitis | 25.79 | 10.89 | 87 | 40799 | 44477 | 50519761 |
Swelling | 25.79 | 10.89 | 80 | 40806 | 200792 | 50363446 |
Hallucination, visual | 25.40 | 10.89 | 47 | 40839 | 16535 | 50547703 |
Vaginal flatulence | 25.30 | 10.89 | 9 | 40877 | 243 | 50563995 |
Febrile neutropenia | 25.21 | 10.89 | 25 | 40861 | 97642 | 50466596 |
Product use issue | 25.01 | 10.89 | 52 | 40834 | 149423 | 50414815 |
Bacterial test | 24.83 | 10.89 | 14 | 40872 | 1143 | 50563095 |
Urinary sediment present | 24.70 | 10.89 | 17 | 40869 | 1974 | 50562264 |
Red blood cells urine positive | 23.85 | 10.89 | 19 | 40867 | 2756 | 50561482 |
Urine abnormality | 23.36 | 10.89 | 27 | 40859 | 6211 | 50558027 |
Injection site scar | 23.03 | 10.89 | 12 | 40874 | 837 | 50563401 |
Myelocyte percentage increased | 22.85 | 10.89 | 8 | 40878 | 206 | 50564032 |
Stomatitis | 22.81 | 10.89 | 29 | 40857 | 101315 | 50462923 |
Band neutrophil count increased | 22.40 | 10.89 | 9 | 40877 | 342 | 50563896 |
Urine oxalate increased | 22.05 | 10.89 | 8 | 40878 | 229 | 50564009 |
Lymphocyte percentage decreased | 21.82 | 10.89 | 18 | 40868 | 2742 | 50561496 |
Head injury | 21.72 | 10.89 | 55 | 40831 | 23965 | 50540273 |
Crystal urine present | 21.69 | 10.89 | 14 | 40872 | 1460 | 50562778 |
Dysmetropsia | 21.18 | 10.89 | 6 | 40880 | 75 | 50564163 |
Retinal depigmentation | 20.70 | 10.89 | 8 | 40878 | 274 | 50563964 |
Amnesia | 20.61 | 10.89 | 78 | 40808 | 42182 | 50522056 |
Lymphocyte count decreased | 20.50 | 10.89 | 57 | 40829 | 26250 | 50537988 |
Nephrolithiasis | 20.31 | 10.89 | 68 | 40818 | 34625 | 50529613 |
Muscle injury | 20.09 | 10.89 | 3 | 40883 | 37108 | 50527130 |
Rash | 19.93 | 10.89 | 242 | 40644 | 437229 | 50127009 |
Prescription drug used without a prescription | 19.88 | 10.89 | 14 | 40872 | 1686 | 50562552 |
Food refusal | 19.67 | 10.89 | 8 | 40878 | 314 | 50563924 |
Thrombocytopenia | 19.25 | 10.89 | 47 | 40839 | 127626 | 50436612 |
Psychotic symptom | 19.05 | 10.89 | 12 | 40874 | 1200 | 50563038 |
Urinary tract infection bacterial | 19.04 | 10.89 | 20 | 40866 | 4139 | 50560099 |
Myelocyte count increased | 18.96 | 10.89 | 8 | 40878 | 345 | 50563893 |
Decubitus ulcer | 18.77 | 10.89 | 30 | 40856 | 9388 | 50554850 |
Memory impairment | 18.74 | 10.89 | 119 | 40767 | 79241 | 50484997 |
Chronic papillomatous dermatitis | 18.40 | 10.89 | 5 | 40881 | 53 | 50564185 |
Therapeutic product effect decreased | 18.30 | 10.89 | 53 | 40833 | 135997 | 50428241 |
Application site irritation | 18.19 | 10.89 | 13 | 40873 | 1602 | 50562636 |
Application site vesicles | 17.83 | 10.89 | 12 | 40874 | 1343 | 50562895 |
Dizziness | 17.80 | 10.89 | 385 | 40501 | 345984 | 50218254 |
Injection related reaction | 17.74 | 10.89 | 9 | 40877 | 594 | 50563644 |
Blister | 17.65 | 10.89 | 26 | 40860 | 85392 | 50478846 |
Lymphopenia | 17.63 | 10.89 | 39 | 40847 | 15582 | 50548656 |
Faecaloma | 17.52 | 10.89 | 25 | 40861 | 7083 | 50557155 |
Alopecia | 17.48 | 10.89 | 121 | 40765 | 244926 | 50319312 |
Product administered at inappropriate site | 17.40 | 10.89 | 15 | 40871 | 2428 | 50561810 |
Abortion spontaneous | 17.40 | 10.89 | 6 | 40880 | 41766 | 50522472 |
Impaired self-care | 17.25 | 10.89 | 13 | 40873 | 1738 | 50562500 |
Peripheral swelling | 17.10 | 10.89 | 97 | 40789 | 205839 | 50358399 |
Nocturia | 17.08 | 10.89 | 24 | 40862 | 6706 | 50557532 |
Discomfort | 17.05 | 10.89 | 39 | 40847 | 108341 | 50455897 |
Dementia | 17.01 | 10.89 | 39 | 40847 | 15958 | 50548280 |
Lagophthalmos | 16.92 | 10.89 | 7 | 40879 | 287 | 50563951 |
Specific gravity urine decreased | 16.63 | 10.89 | 9 | 40877 | 678 | 50563560 |
Dermatitis contact | 16.50 | 10.89 | 27 | 40859 | 8619 | 50555619 |
Urine odour abnormal | 16.45 | 10.89 | 21 | 40865 | 5352 | 50558886 |
Porphyria acute | 16.34 | 10.89 | 8 | 40878 | 489 | 50563749 |
Resting tremor | 16.16 | 10.89 | 9 | 40877 | 717 | 50563521 |
Proctitis | 16.14 | 10.89 | 13 | 40873 | 1915 | 50562323 |
Lower respiratory tract infection | 16.02 | 10.89 | 33 | 40853 | 95168 | 50469070 |
Cerebrovascular accident | 16.01 | 10.89 | 131 | 40755 | 94549 | 50469689 |
Urinary tract infection pseudomonal | 15.42 | 10.89 | 9 | 40877 | 784 | 50563454 |
Stress urinary incontinence | 15.36 | 10.89 | 13 | 40873 | 2052 | 50562186 |
Pyelonephritis | 15.34 | 10.89 | 36 | 40850 | 14953 | 50549285 |
Pain | 15.27 | 10.89 | 354 | 40532 | 578549 | 49985689 |
Peroneal nerve palsy | 15.15 | 10.89 | 18 | 40868 | 4265 | 50559973 |
Constipation | 14.69 | 10.89 | 221 | 40665 | 185487 | 50378751 |
Drug abuse | 14.67 | 10.89 | 16 | 40870 | 59830 | 50504408 |
Body height decreased | 14.60 | 10.89 | 26 | 40860 | 8882 | 50555356 |
Product complaint | 14.52 | 10.89 | 30 | 40856 | 11436 | 50552802 |
Nasopharyngitis | 14.38 | 10.89 | 94 | 40792 | 192833 | 50371405 |
Therapeutic product effect incomplete | 14.34 | 10.89 | 33 | 40853 | 91482 | 50472756 |
Thyroglobulin increased | 14.19 | 10.89 | 4 | 40882 | 49 | 50564189 |
Neutrophil percentage increased | 14.09 | 10.89 | 14 | 40872 | 2713 | 50561525 |
Neutropenia | 13.79 | 10.89 | 67 | 40819 | 147898 | 50416340 |
Urinary tract disorder | 13.77 | 10.89 | 13 | 40873 | 2367 | 50561871 |
Repetitive strain injury | 13.41 | 10.89 | 5 | 40881 | 155 | 50564083 |
Cardiac failure congestive | 13.33 | 10.89 | 115 | 40771 | 84267 | 50479971 |
Somnolence | 13.26 | 10.89 | 187 | 40699 | 154798 | 50409440 |
Open fracture | 13.05 | 10.89 | 6 | 40880 | 318 | 50563920 |
Vertigo | 13.04 | 10.89 | 79 | 40807 | 51753 | 50512485 |
Hip fracture | 12.75 | 10.89 | 48 | 40838 | 25883 | 50538355 |
Pregnancy | 12.75 | 10.89 | 4 | 40882 | 29573 | 50534665 |
Haemoglobin urine present | 12.72 | 10.89 | 8 | 40878 | 798 | 50563440 |
Red blood cell sedimentation rate increased | 12.64 | 10.89 | 4 | 40882 | 29412 | 50534826 |
Anaemia folate deficiency | 12.60 | 10.89 | 5 | 40881 | 184 | 50564054 |
Product closure removal difficult | 12.54 | 10.89 | 3 | 40883 | 18 | 50564220 |
Chronic obstructive pulmonary disease | 12.54 | 10.89 | 80 | 40806 | 53355 | 50510883 |
Seizure | 12.52 | 10.89 | 148 | 40738 | 117726 | 50446512 |
Hallucinations, mixed | 12.50 | 10.89 | 16 | 40870 | 4087 | 50560151 |
Drug withdrawal syndrome neonatal | 12.50 | 10.89 | 11 | 40875 | 1830 | 50562408 |
Mixed incontinence | 12.37 | 10.89 | 4 | 40882 | 80 | 50564158 |
Female genital tract fistula | 12.30 | 10.89 | 15 | 40871 | 3651 | 50560587 |
Device expulsion | 12.25 | 10.89 | 4 | 40882 | 28818 | 50535420 |
Hypersensitivity | 12.21 | 10.89 | 113 | 40773 | 215048 | 50349190 |
Coordination abnormal | 12.13 | 10.89 | 28 | 40858 | 11506 | 50552732 |
Incision site pruritus | 11.69 | 10.89 | 3 | 40883 | 25 | 50564213 |
Klebsiella test positive | 11.67 | 10.89 | 8 | 40878 | 923 | 50563315 |
Basophil count decreased | 11.65 | 10.89 | 4 | 40882 | 97 | 50564141 |
Radiculopathy | 11.63 | 10.89 | 17 | 40869 | 4924 | 50559314 |
Anaphylactic reaction | 11.62 | 10.89 | 16 | 40870 | 54039 | 50510199 |
Hepatic function abnormal | 11.52 | 10.89 | 6 | 40880 | 32675 | 50531563 |
Bone marrow failure | 11.45 | 10.89 | 4 | 40882 | 27620 | 50536618 |
Bladder pain | 11.41 | 10.89 | 10 | 40876 | 1654 | 50562584 |
Dysarthria | 11.38 | 10.89 | 60 | 40826 | 37343 | 50526895 |
Interstitial lung disease | 11.17 | 10.89 | 16 | 40870 | 53160 | 50511078 |
Intentional overdose | 11.08 | 10.89 | 21 | 40865 | 62483 | 50501755 |
Therapy cessation | 11.06 | 10.89 | 46 | 40840 | 25965 | 50538273 |
Urge incontinence | 11.06 | 10.89 | 7 | 40879 | 706 | 50563532 |
Product use in unapproved indication | 11.05 | 10.89 | 52 | 40834 | 115767 | 50448471 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 162.49 | 12.79 | 188 | 14247 | 72166 | 29487926 |
Dry mouth | 94.28 | 12.79 | 81 | 14354 | 21703 | 29538389 |
Confusional state | 75.69 | 12.79 | 182 | 14253 | 127695 | 29432397 |
Multiple sclerosis relapse | 69.78 | 12.79 | 52 | 14383 | 11367 | 29548725 |
Fall | 67.87 | 12.79 | 215 | 14220 | 176963 | 29383129 |
Multiple sclerosis | 57.28 | 12.79 | 35 | 14400 | 5519 | 29554573 |
Bladder spasm | 43.18 | 12.79 | 16 | 14419 | 817 | 29559275 |
Muscle spasticity | 40.94 | 12.79 | 27 | 14408 | 4856 | 29555236 |
Urinary retention | 40.71 | 12.79 | 63 | 14372 | 31835 | 29528257 |
Constipation | 31.88 | 12.79 | 125 | 14310 | 114035 | 29446057 |
Disorganised speech | 31.34 | 12.79 | 12 | 14423 | 671 | 29559421 |
Completed suicide | 24.52 | 12.79 | 98 | 14337 | 90148 | 29469944 |
Daydreaming | 24.04 | 12.79 | 9 | 14426 | 473 | 29559619 |
Hallucination | 20.56 | 12.79 | 58 | 14377 | 44654 | 29515438 |
Dysuria | 20.25 | 12.79 | 38 | 14397 | 22402 | 29537690 |
Micturition urgency | 19.89 | 12.79 | 18 | 14417 | 5155 | 29554937 |
Urosepsis | 19.30 | 12.79 | 25 | 14410 | 10721 | 29549371 |
Escherichia urinary tract infection | 18.92 | 12.79 | 14 | 14421 | 3025 | 29557067 |
Urinary incontinence | 18.88 | 12.79 | 31 | 14404 | 16450 | 29543642 |
Interstitial lung disease | 18.47 | 12.79 | 3 | 14432 | 57715 | 29502377 |
Nephrolithiasis | 18.19 | 12.79 | 39 | 14396 | 25295 | 29534797 |
Decubitus ulcer | 18.05 | 12.79 | 20 | 14415 | 7291 | 29552801 |
Perthes disease | 17.80 | 12.79 | 3 | 14432 | 3 | 29560089 |
Syncope | 17.23 | 12.79 | 82 | 14353 | 81289 | 29478803 |
Gait disturbance | 17.07 | 12.79 | 76 | 14359 | 73273 | 29486819 |
Delirium | 17.04 | 12.79 | 50 | 14385 | 39347 | 29520745 |
Dizziness | 16.57 | 12.79 | 153 | 14282 | 189531 | 29370561 |
Neurogenic bladder | 16.34 | 12.79 | 10 | 14425 | 1580 | 29558512 |
Cystitis interstitial | 15.88 | 12.79 | 5 | 14430 | 155 | 29559937 |
Intestinal pseudo-obstruction | 15.58 | 12.79 | 9 | 14426 | 1279 | 29558813 |
Cognitive disorder | 15.54 | 12.79 | 35 | 14400 | 23464 | 29536628 |
Amnesia | 15.28 | 12.79 | 34 | 14401 | 22609 | 29537483 |
Rib hypoplasia | 15.05 | 12.79 | 3 | 14432 | 12 | 29560080 |
Implant site erosion | 14.71 | 12.79 | 4 | 14431 | 73 | 29560019 |
Vision blurred | 14.61 | 12.79 | 48 | 14387 | 40128 | 29519964 |
Pollakiuria | 14.46 | 12.79 | 28 | 14407 | 16888 | 29543204 |
Pulmonary hypoplasia | 14.38 | 12.79 | 6 | 14429 | 420 | 29559672 |
Localised oedema | 14.18 | 12.79 | 12 | 14423 | 3144 | 29556948 |
Granulocytopenia | 14.12 | 12.79 | 16 | 14419 | 5978 | 29554114 |
Haemorrhage urinary tract | 13.80 | 12.79 | 9 | 14426 | 1587 | 29558505 |
Haematuria | 13.67 | 12.79 | 50 | 14385 | 44089 | 29516003 |
Tongue haemorrhage | 13.50 | 12.79 | 6 | 14429 | 490 | 29559602 |
Bladder catheterisation | 13.38 | 12.79 | 6 | 14429 | 501 | 29559591 |
Hepatitis acute | 13.14 | 12.79 | 16 | 14419 | 6446 | 29553646 |
Hallucination, tactile | 13.14 | 12.79 | 5 | 14430 | 275 | 29559817 |
Balance disorder | 12.96 | 12.79 | 43 | 14392 | 36127 | 29523965 |
Mental status changes | 12.94 | 12.79 | 42 | 14393 | 34885 | 29525207 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 358.43 | 10.46 | 600 | 43641 | 230996 | 64223495 |
Multiple sclerosis relapse | 254.31 | 10.46 | 217 | 44024 | 40918 | 64413573 |
Fall | 214.65 | 10.46 | 700 | 43541 | 416126 | 64038365 |
Multiple sclerosis | 162.13 | 10.46 | 121 | 44120 | 18820 | 64435671 |
Dry mouth | 141.01 | 10.46 | 190 | 44051 | 60228 | 64394263 |
Urinary incontinence | 77.27 | 10.46 | 109 | 44132 | 36042 | 64418449 |
Confusional state | 68.00 | 10.46 | 356 | 43885 | 260788 | 64193703 |
Urine analysis abnormal | 63.65 | 10.46 | 43 | 44198 | 5713 | 64448778 |
Application site erythema | 61.55 | 10.46 | 39 | 44202 | 4650 | 64449841 |
Laboratory test abnormal | 53.57 | 10.46 | 74 | 44167 | 23989 | 64430502 |
Neurogenic bladder | 52.30 | 10.46 | 32 | 44209 | 3587 | 64450904 |
Gait disturbance | 51.35 | 10.46 | 244 | 43997 | 171911 | 64282580 |
Bladder spasm | 49.28 | 10.46 | 25 | 44216 | 1947 | 64452544 |
Escherichia urinary tract infection | 48.33 | 10.46 | 50 | 44191 | 11987 | 64442504 |
Muscle spasticity | 47.64 | 10.46 | 58 | 44183 | 16611 | 64437880 |
Micturition urgency | 47.04 | 10.46 | 46 | 44195 | 10313 | 64444178 |
Application site pruritus | 45.37 | 10.46 | 29 | 44212 | 3510 | 64450981 |
Treatment failure | 43.54 | 10.46 | 13 | 44228 | 116803 | 64337688 |
Mental status changes | 41.97 | 10.46 | 114 | 44127 | 61048 | 64393443 |
Urinary retention | 41.34 | 10.46 | 99 | 44142 | 49102 | 64405389 |
Dysuria | 41.29 | 10.46 | 90 | 44151 | 41967 | 64412524 |
Balance disorder | 41.18 | 10.46 | 139 | 44102 | 83787 | 64370704 |
Synovitis | 38.84 | 10.46 | 10 | 44231 | 99080 | 64355411 |
Joint swelling | 37.51 | 10.46 | 56 | 44185 | 215326 | 64239165 |
Off label use | 37.14 | 10.46 | 268 | 43973 | 632538 | 63821953 |
Nephrolithiasis | 36.81 | 10.46 | 88 | 44153 | 43595 | 64410896 |
White blood cells urine positive | 36.48 | 10.46 | 30 | 44211 | 5368 | 64449123 |
Bladder disorder | 36.22 | 10.46 | 35 | 44206 | 7732 | 64446759 |
Drug intolerance | 33.59 | 10.46 | 48 | 44193 | 187944 | 64266547 |
Hallucination | 33.47 | 10.46 | 118 | 44123 | 72670 | 64381821 |
Maternal exposure during pregnancy | 33.39 | 10.46 | 12 | 44229 | 95872 | 64358619 |
Culture urine positive | 32.17 | 10.46 | 25 | 44216 | 4126 | 64450365 |
Gait inability | 32.15 | 10.46 | 82 | 44159 | 42286 | 64412205 |
Systemic lupus erythematosus | 32.06 | 10.46 | 7 | 44234 | 77605 | 64376886 |
Muscular weakness | 31.98 | 10.46 | 172 | 44069 | 127166 | 64327325 |
Urine leukocyte esterase positive | 31.96 | 10.46 | 23 | 44218 | 3380 | 64451111 |
Depression | 31.21 | 10.46 | 224 | 44017 | 183067 | 64271424 |
Pollakiuria | 30.41 | 10.46 | 67 | 44174 | 31463 | 64423028 |
Cystitis | 29.73 | 10.46 | 80 | 44161 | 42595 | 64411896 |
Urinary tract infection bacterial | 29.56 | 10.46 | 26 | 44215 | 5095 | 64449396 |
Infusion related reaction | 29.37 | 10.46 | 42 | 44199 | 164425 | 64290066 |
Secondary progressive multiple sclerosis | 28.87 | 10.46 | 15 | 44226 | 1228 | 64453263 |
Interstitial lung disease | 28.14 | 10.46 | 16 | 44225 | 97716 | 64356775 |
Hypertonic bladder | 27.39 | 10.46 | 21 | 44220 | 3397 | 64451094 |
Hallucination, visual | 26.68 | 10.46 | 59 | 44182 | 27775 | 64426716 |
Incontinence | 26.66 | 10.46 | 37 | 44204 | 12044 | 64442447 |
Exposure during pregnancy | 26.57 | 10.46 | 10 | 44231 | 77665 | 64376826 |
Bacterial test | 26.42 | 10.46 | 14 | 44227 | 1193 | 64453298 |
Urinary sediment present | 25.44 | 10.46 | 17 | 44224 | 2217 | 64452274 |
Hepatic enzyme increased | 25.43 | 10.46 | 31 | 44210 | 129912 | 64324579 |
Impaired self-care | 24.91 | 10.46 | 17 | 44224 | 2296 | 64452195 |
Intestinal pseudo-obstruction | 24.68 | 10.46 | 16 | 44225 | 1984 | 64452507 |
Drug abuse | 24.44 | 10.46 | 33 | 44208 | 132341 | 64322150 |
Hepatic function abnormal | 24.24 | 10.46 | 7 | 44234 | 64306 | 64390185 |
Malignant neoplasm progression | 24.19 | 10.46 | 25 | 44216 | 112846 | 64341645 |
Asthenia | 24.16 | 10.46 | 420 | 43821 | 427624 | 64026867 |
Decubitus ulcer | 23.77 | 10.46 | 37 | 44204 | 13342 | 64441149 |
Amnesia | 23.71 | 10.46 | 80 | 44161 | 48189 | 64406302 |
Urine oxalate increased | 23.57 | 10.46 | 8 | 44233 | 222 | 64454269 |
Cerebral atrophy | 23.55 | 10.46 | 27 | 44214 | 7258 | 64447233 |
Thrombocytopenia | 23.45 | 10.46 | 77 | 44164 | 223724 | 64230767 |
Dementia | 23.37 | 10.46 | 47 | 44194 | 20719 | 64433772 |
Urine abnormality | 23.32 | 10.46 | 27 | 44214 | 7335 | 64447156 |
Granulocytopenia | 23.08 | 10.46 | 32 | 44209 | 10408 | 64444083 |
Myelocyte percentage increased | 22.88 | 10.46 | 8 | 44233 | 243 | 64454248 |
Band neutrophil percentage increased | 22.65 | 10.46 | 9 | 44232 | 393 | 64454098 |
Application site rash | 22.57 | 10.46 | 15 | 44226 | 1939 | 64452552 |
Hallucinations, mixed | 22.27 | 10.46 | 24 | 44217 | 6028 | 64448463 |
Dizziness | 21.78 | 10.46 | 415 | 43826 | 429748 | 64024743 |
Dysmetropsia | 21.46 | 10.46 | 6 | 44235 | 85 | 64454406 |
Retinal depigmentation | 20.94 | 10.46 | 8 | 44233 | 314 | 64454177 |
Febrile neutropenia | 20.75 | 10.46 | 63 | 44178 | 187594 | 64266897 |
Pyelonephritis | 20.54 | 10.46 | 40 | 44201 | 17226 | 64437265 |
Constipation | 20.50 | 10.46 | 244 | 43997 | 229093 | 64225398 |
Crystal urine present | 20.35 | 10.46 | 14 | 44227 | 1915 | 64452576 |
Faecaloma | 20.29 | 10.46 | 29 | 44212 | 9699 | 64444792 |
Stress urinary incontinence | 20.25 | 10.46 | 13 | 44228 | 1585 | 64452906 |
Urosepsis | 20.24 | 10.46 | 46 | 44195 | 22048 | 64432443 |
Monocyte percentage increased | 19.89 | 10.46 | 14 | 44227 | 1986 | 64452505 |
Disorganised speech | 19.87 | 10.46 | 13 | 44228 | 1637 | 64452854 |
Specific gravity urine decreased | 19.78 | 10.46 | 10 | 44231 | 773 | 64453718 |
Glossodynia | 19.49 | 10.46 | 10 | 44231 | 64686 | 64389805 |
Daydreaming | 19.46 | 10.46 | 10 | 44231 | 800 | 64453691 |
Renal impairment | 19.06 | 10.46 | 40 | 44201 | 134977 | 64319514 |
Bladder pain | 18.97 | 10.46 | 13 | 44228 | 1768 | 64452723 |
Red blood cells urine positive | 18.70 | 10.46 | 19 | 44222 | 4459 | 64450032 |
Band neutrophil count increased | 18.43 | 10.46 | 9 | 44232 | 646 | 64453845 |
Injection related reaction | 18.27 | 10.46 | 9 | 44232 | 658 | 64453833 |
Food refusal | 18.26 | 10.46 | 8 | 44233 | 447 | 64454044 |
Body height decreased | 17.98 | 10.46 | 24 | 44217 | 7530 | 64446961 |
General physical health deterioration | 17.72 | 10.46 | 76 | 44165 | 204349 | 64250142 |
Dermatitis contact | 17.56 | 10.46 | 26 | 44215 | 8974 | 64445517 |
Product adhesion issue | 17.32 | 10.46 | 14 | 44227 | 2445 | 64452046 |
Abdominal discomfort | 16.92 | 10.46 | 66 | 44175 | 182256 | 64272235 |
Psychotic symptom | 16.84 | 10.46 | 13 | 44228 | 2125 | 64452366 |
Dysarthria | 16.82 | 10.46 | 83 | 44158 | 59323 | 64395168 |
Neutropenia | 16.79 | 10.46 | 96 | 44145 | 239528 | 64214963 |
Perthes disease | 16.78 | 10.46 | 3 | 44238 | 3 | 64454488 |
Lagophthalmos | 16.77 | 10.46 | 7 | 44234 | 347 | 64454144 |
Bone marrow failure | 16.69 | 10.46 | 6 | 44235 | 47946 | 64406545 |
Urinary tract infection pseudomonal | 16.54 | 10.46 | 11 | 44230 | 1423 | 64453068 |
Product use in unapproved indication | 16.34 | 10.46 | 64 | 44177 | 176554 | 64277937 |
Lymphocyte percentage decreased | 16.34 | 10.46 | 18 | 44223 | 4631 | 64449860 |
Multiple organ dysfunction syndrome | 16.10 | 10.46 | 28 | 44213 | 101385 | 64353106 |
Syncope | 16.02 | 10.46 | 172 | 44069 | 157463 | 64297028 |
Abnormal behaviour | 15.88 | 10.46 | 55 | 44186 | 33567 | 64420924 |
Urge incontinence | 15.41 | 10.46 | 9 | 44232 | 927 | 64453564 |
Wound | 15.22 | 10.46 | 18 | 44223 | 76459 | 64378032 |
Application site vesicles | 14.91 | 10.46 | 10 | 44231 | 1312 | 64453179 |
Urine odour abnormal | 14.89 | 10.46 | 18 | 44223 | 5118 | 64449373 |
Porphyria acute | 14.77 | 10.46 | 8 | 44233 | 712 | 64453779 |
Hydronephrosis | 14.75 | 10.46 | 31 | 44210 | 14094 | 64440397 |
Memory impairment | 14.73 | 10.46 | 105 | 44136 | 85577 | 64368914 |
Prescription drug used without a prescription | 14.61 | 10.46 | 13 | 44228 | 2587 | 64451904 |
Repetitive strain injury | 14.49 | 10.46 | 5 | 44236 | 146 | 64454345 |
Product administered at inappropriate site | 14.48 | 10.46 | 14 | 44227 | 3096 | 64451395 |
Myelocyte count increased | 14.45 | 10.46 | 8 | 44233 | 744 | 64453747 |
Urinary tract disorder | 14.26 | 10.46 | 14 | 44227 | 3152 | 64451339 |
Rash | 14.25 | 10.46 | 225 | 44016 | 458324 | 63996167 |
Thyroglobulin increased | 14.22 | 10.46 | 4 | 44237 | 58 | 64454433 |
Toxic epidermal necrolysis | 14.09 | 10.46 | 4 | 44237 | 37162 | 64417329 |
Drug reaction with eosinophilia and systemic symptoms | 14.06 | 10.46 | 10 | 44231 | 54207 | 64400284 |
Visual impairment | 14.05 | 10.46 | 93 | 44148 | 73984 | 64380507 |
Progressive multiple sclerosis | 14.02 | 10.46 | 8 | 44233 | 788 | 64453703 |
Delirium | 13.81 | 10.46 | 88 | 44153 | 69106 | 64385385 |
Vision blurred | 13.45 | 10.46 | 107 | 44134 | 90209 | 64364282 |
Haemoglobin urine present | 13.42 | 10.46 | 8 | 44233 | 855 | 64453636 |
Product use issue | 13.39 | 10.46 | 56 | 44185 | 151659 | 64302832 |
Head injury | 13.21 | 10.46 | 51 | 44190 | 32791 | 64421700 |
Shock | 12.95 | 10.46 | 5 | 44236 | 38235 | 64416256 |
Open fracture | 12.93 | 10.46 | 6 | 44235 | 384 | 64454107 |
Wrist fracture | 12.92 | 10.46 | 24 | 44217 | 9977 | 64444514 |
Stomatitis | 12.69 | 10.46 | 36 | 44205 | 109569 | 64344922 |
Duodenal ulcer perforation | 12.63 | 10.46 | 4 | 44237 | 34621 | 64419870 |
Product dose omission issue | 12.39 | 10.46 | 195 | 44046 | 194552 | 64259939 |
Cytomegalovirus infection | 12.37 | 10.46 | 5 | 44236 | 37194 | 64417297 |
Somnolence | 12.24 | 10.46 | 202 | 44039 | 203443 | 64251048 |
Nocturia | 12.24 | 10.46 | 25 | 44216 | 11140 | 64443351 |
Product complaint | 12.21 | 10.46 | 26 | 44215 | 11928 | 64442563 |
Toxicity to various agents | 12.10 | 10.46 | 176 | 44065 | 363337 | 64091154 |
Injection site scar | 12.09 | 10.46 | 7 | 44234 | 709 | 64453782 |
Anaemia folate deficiency | 12.04 | 10.46 | 5 | 44236 | 245 | 64454246 |
Kidney infection | 11.98 | 10.46 | 33 | 44208 | 17805 | 64436686 |
Ascites | 11.91 | 10.46 | 15 | 44226 | 61986 | 64392505 |
Speech disorder | 11.86 | 10.46 | 65 | 44176 | 48376 | 64406115 |
Folliculitis | 11.85 | 10.46 | 3 | 44238 | 30074 | 64424417 |
Lymphocyte count decreased | 11.62 | 10.46 | 57 | 44184 | 40642 | 64413849 |
Incision site pruritus | 11.59 | 10.46 | 3 | 44238 | 31 | 64454460 |
Cystitis interstitial | 11.44 | 10.46 | 8 | 44233 | 1124 | 64453367 |
Blood urine present | 11.41 | 10.46 | 33 | 44208 | 18307 | 64436184 |
Swelling | 11.32 | 10.46 | 64 | 44177 | 160154 | 64294337 |
Liver disorder | 11.22 | 10.46 | 12 | 44229 | 53339 | 64401152 |
Arthropathy | 11.08 | 10.46 | 44 | 44197 | 120923 | 64333568 |
Salivary gland disorder | 10.91 | 10.46 | 5 | 44236 | 311 | 64454180 |
Tongue haemorrhage | 10.88 | 10.46 | 7 | 44234 | 856 | 64453635 |
Cerebrovascular accident | 10.83 | 10.46 | 143 | 44098 | 137440 | 64317051 |
Red blood cell sedimentation rate increased | 10.72 | 10.46 | 4 | 44237 | 31231 | 64423260 |
Ankle fracture | 10.67 | 10.46 | 28 | 44213 | 14682 | 64439809 |
Lactic acidosis | 10.64 | 10.46 | 16 | 44225 | 61394 | 64393097 |
Haematocrit decreased | 10.59 | 10.46 | 69 | 44172 | 54586 | 64399905 |
Anticholinergic syndrome | 10.56 | 10.46 | 11 | 44230 | 2658 | 64451833 |
Vertigo | 10.54 | 10.46 | 73 | 44168 | 58938 | 64395553 |
None
Source | Code | Description |
---|---|---|
ATC | G04BD04 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
FDA MoA | N0000000125 | Cholinergic Muscarinic Antagonists |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D018727 | Muscarinic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D010276 | Parasympatholytics |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D064804 | Urological Agents |
CHEBI has role | CHEBI:36333 | local anesthetics |
CHEBI has role | CHEBI:38215 | calcium channel blockers |
CHEBI has role | CHEBI:48876 | muscarinic antagonists |
CHEBI has role | CHEBI:50370 | parasympatholytics |
CHEBI has role | CHEBI:51371 | muscle relaxants |
CHEBI has role | CHEBI:53784 | antispasmodics |
FDA EPC | N0000175700 | Cholinergic Muscarinic Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Urgent desire to urinate | indication | 75088002 | |
Urge incontinence of urine | indication | 87557004 | |
Bladder muscle dysfunction - overactive | indication | 236633002 | |
Neurogenic bladder | indication | 398064005 | |
Increased Urinary Frequency | indication | ||
Sinus tachycardia | contraindication | 11092001 | |
Severe chronic ulcerative colitis | contraindication | 14311001 | |
Toxic megacolon | contraindication | 28536002 | DOID:1770 |
Atony of colon | contraindication | 29479008 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Hiatal hernia | contraindication | 84089009 | DOID:12642 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Bladder outflow obstruction | contraindication | 236645006 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Drowsy | contraindication | 271782001 | |
Gastric retention | contraindication | 307227006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Disorder of coronary artery | contraindication | 414024009 | |
Gastrointestinal hypomotility | contraindication | 421807004 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.67 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
10% (100MG/PACKET) | GELNIQUE | ALLERGAN | N022204 | Jan. 27, 2009 | RX | GEL | TRANSDERMAL | 10449173 | Nov. 6, 2029 | TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL |
10% (100MG/PACKET) | GELNIQUE | ALLERGAN | N022204 | Jan. 27, 2009 | RX | GEL | TRANSDERMAL | 9259388 | Nov. 6, 2029 | TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN |
10% (100MG/PACKET) | GELNIQUE | ALLERGAN | N022204 | Jan. 27, 2009 | RX | GEL | TRANSDERMAL | 8920392 | March 26, 2031 | TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | Ki | 9 | CHEMBL | DRUG LABEL | |||
Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 9.11 | CHEMBL | DRUG LABEL | |||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.30 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.84 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 8.09 | CHEMBL | ||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.44 | CHEMBL | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.85 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.99 | DRUG MATRIX | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 6.22 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 7.17 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.59 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.09 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.16 | CHEMBL | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.23 | CHEMBL | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 9.02 | CHEMBL |
ID | Source |
---|---|
4018815 | VUID |
N0000147118 | NUI |
D00465 | KEGG_DRUG |
1508-65-2 | SECONDARY_CAS_RN |
4018815 | VANDF |
4019869 | VANDF |
C0069805 | UMLSCUI |
CHEBI:7856 | CHEBI |
CHEMBL1231 | ChEMBL_ID |
CHEMBL1133 | ChEMBL_ID |
DB01062 | DRUGBANK_ID |
C005419 | MESH_SUPPLEMENTAL_RECORD_UI |
4634 | PUBCHEM_CID |
359 | IUPHAR_LIGAND_ID |
1354 | INN_ID |
K9P6MC7092 | UNII |
151651 | RXNORM |
180 | MMSL |
28244 | MMSL |
4610 | MMSL |
46359 | MMSL |
5214 | MMSL |
d00328 | MMSL |
001768 | NDDF |
004715 | NDDF |
31815007 | SNOMEDCT_US |
35768004 | SNOMEDCT_US |
372717000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5812 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5861 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
OXYTROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-6153 | PATCH | 3.90 mg | TRANSDERMAL | NDA | 27 sections |
Oxytrol for Women | HUMAN OTC DRUG LABEL | 1 | 0023-9637 | PATCH | 3.90 mg | TRANSDERMAL | NDA | 14 sections |
OXYBUTYNIN CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0671 | SYRUP | 5 mg | ORAL | ANDA | 18 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-4975 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-4975 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-3512 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-3512 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
oxybutynin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8219 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8220 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0038 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-2821 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6570 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 25 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7027 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-609 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-610 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-611 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-640 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-518 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-559 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-201 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14539-653 | TABLET | 5 mg | ORAL | ANDA | 13 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-317 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 26 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-318 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-319 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0092 | SYRUP | 5 mg | ORAL | ANDA | 17 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0149 | SYRUP | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-1491 | SOLUTION | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-406 | TABLET | 5 mg | ORAL | ANDA | 23 sections |